Research programme: fibrosis therapeutics - MitoImmune Therapeutics
Latest Information Update: 16 Jan 2023
At a glance
- Originator MitoImmune Therapeutics
- Class Antifibrotics; Hepatoprotectants
- Mechanism of Action Cell death modulators; Ferroptosis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Idiopathic pulmonary fibrosis; Non-alcoholic steatohepatitis
Most Recent Events
- 05 Jan 2023 Early research in Idiopathic pulmonary fibrosis in South Korea (PO) before January 2023 (MitoImmune Therapeutics pipeline, January 2023)
- 05 Jan 2023 Early research in Non-alcoholic steatohepatitis in South Korea (PO) before January 2023 (MitoImmune Therapeutics pipeline, January 2023)